Skip to content

Opening book details…

About this Medicine article

WS19.2 Long-term safety of lumacaftor/ivacaftor therapy in persons with cystic fibrosis aged 2–5 years homozygous for the F508del-CFTR mutation (F/F) by Hoppe, J.; Chilvers, M.; Ratjen, F.; McNamara, J.J.; Owen, C.A.; Tian, S.; Zahigian, R.; Cornell, A.G.; McColley, S.A. is a Medicine article available to read on EtoBox.

It is typically read by researchers, students, and practitioners in Medicine.

Author
Hoppe, J.; Chilvers, M.; Ratjen, F.; McNamara, J.J.; Owen, C.A.; Tian, S.; Zahigian, R.; Cornell, A.G.; McColley, S.A.
Publisher
Elsevier Science; Elsevier ; Elsevier BV (ISSN 1569-1993)
Published
2020
Field
Medicine (Health Sciences)

More by Hoppe, J.; Chilvers, M.; Ratjen, F.; McNamara, J.J.; Owen, C.A.; Tian, S.; Zahigian, R.; Cornell, A.G.; McColley, S.A.

Browse all works by Hoppe, J.; Chilvers, M.; Ratjen, F.; McNamara, J.J.; Owen, C.A.; Tian, S.; Zahigian, R.; Cornell, A.G.; McColley, S.A.